India Pharma Outlook Team | Monday, 11 August 2025
Entod Pharmaceuticals, a leader in ophthalmology, ENT, and dermatology medicines, has announced a number of innovative changes among its specialty divisions that will help to strengthen India’s position in global pharmaceutical R&D.
Entod is a company focused on indigenously developed medicines that meet international standards, with a well-established state-of-the-art R&D centre in Mumbai. They have a wide variety of specialty medicines in the pipeline that will improve patient outcomes in domestic and global marketplaces.
Among these is the launch of the world's first eye drop for slowing the progression of myopia in children 6-12 years of age. This is a serious prescription-only therapy that is specifically targeted to alleviate the rising epidemic of childhood myopia, and supports Entod's already strong position in the paediatric ophthalmology business.
Entod is also integrating research into corneal disorders to develop next generation preservative-free, biocompatible ophthalmic solutions. These will protect and restore corneal surface function that has become very popular as a very sensitive tissue in both old and new patient populations.
Also Read: Personalized Hygiene Care Tailoring Products to Individual Needs
Entod harnesses dermatological expertise with its latest,stage-advanced skincare product, a collagen-based transdermal gel serum designed to regenerate the skin, in multiple layers deep. Designed to encourage the body to regenerate through natural collagen synthesis and repair, the product contains bioactive peptides, plant derivatives, and skin-mimetic delivery technology to enhance the firmness, texture and elasticity of the skin, and is on target to make a market entry early, and become a true innovator ahead of the global competition in the regenerative skincare category.
"Our focus has always been to close real gaps in healthcare with innovation driven by science," said Nikkhil K Masurkar, CEO of Entod Pharmaceuticals. "We are making differences from paediatric eye care to next-generation skincare and building the future of healthcare as we do."
With more than 300 medicines exported to 67 countries around the world and nearly 5 decades of experience, Entod, is not only a leading exporter, but continues to expand its presence in global markets by transforming patient-centred, India-first innovations into products for healthcare professionals, patient, and society.
